# Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer

> **NCT00001507** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 107 (actual)

## Conditions studied

- Breast Neoplasm
- Neoplasm Metastasis

## Interventions

- **DRUG:** Monoclonal Antibody 3A1
- **DRUG:** Monoclonal Antibody 95-5-49
- **DRUG:** Monoclonal Antibody 95-6-22
- **DEVICE:** Baxter Isolex 3001 Stem Cell Selection System
- **DEVICE:** Ceprate SC

## Key facts

- **NCT ID:** NCT00001507
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07-12
- **Primary completion:** 1998-06-30
- **Final completion:** 2014-06-20
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001507, "Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00001507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*